Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL4718 Target Snapshot

MAP kinase-interacting serine/threonine-protein kinase 1 · SINGLE PROTEIN · Homo sapiens

2,658Compounds
391Assays
8Approved Drugs
2,144.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-13

Protein identity stays anchored to UniProt Q9BUB5. Use UniProt Q9BUB5 as the stable identity anchor, then attach disease evidence before program review.

Review focus
Protein anchor ready

Use UniProt Q9BUB5 as the stable identity anchor, then attach disease evidence before program review.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-13
Open source guide
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats MAP kinase-interacting serine/threonine-protein kinase 1 as ChEMBL target CHEMBL4718, mapped to UniProt Q9BUB5. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
MAP kinase-interacting serine/threonine-protein kinase 1
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL4718
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
Q9BUB5
MAP kinase-interacting serine/threonine-protein kinase 1
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether MAP kinase-interacting serine/threonine-protein kinase 1 is the right protein anchor across sources, using UniProt Q9BUB5 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need the strongest disease program and evidence level in one place.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelMAP kinase-interacting serine/threonine-protein kinase 1
UniProt AccessionQ9BUB5
Component TypeProtein
Sequence Length465 aa

MAP kinase-interacting serine/threonine-protein kinase 1

Source · UniProt accession via ChEMBL component mapping
Review Cue

How to read this target

Review this target as MAP kinase-interacting serine/threonine-protein kinase 1, mapped to UniProt Q9BUB5. Sequence length is 465 aa.

Mapped IDQ9BUB5
Review nameMAP kinase-interacting serine/threonine-protein kinase 1
OrganismHomo sapiens
Clinical Profile

Clinical Phase Distribution

8
Approved
4
Phase III
11
Phase II
4
Phase I
Assay Mix

Activity Type Distribution

IC501,968.0
KI54.0
KD122.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL5855544 10.0 IC50 0.1 Preclinical
CHEMBL4879010 9.82 IC50 0.15 Preclinical
CHEMBL5984153 9.52 IC50 0.3 Preclinical
CHEMBL6052925 9.52 IC50 0.3 Preclinical
CHEMBL5844466 9.4 IC50 0.4 Preclinical
CHEMBL6002798 9.3 IC50 0.5 Preclinical
CHEMBL4073743 9.29 IC50 0.51 Preclinical
CHEMBL5771700 9.22 IC50 0.6 Preclinical
CHEMBL4076439 9.19 IC50 0.65 Preclinical
CHEMBL5885279 9.15 IC50 0.7 Preclinical
Distribution

pChEMBL Value Distribution

139
5.0
160
5.5
158
6.0
159
6.5
325
7.0
287
7.5
230
8.0
96
8.5
39
9.0
4
9.5
pChEMBL
Approved Drugs

Approved Drugs

BRIGATINIB
CHEMBL3545311
Approved 2017
VANDETANIB
CHEMBL24828
Approved 2011
SORAFENIB
CHEMBL1336
Approved 2005
ERLOTINIB
CHEMBL553
Approved 2004
GEFITINIB
CHEMBL939
Approved 2003
Assay Landscape

Assay Landscape

391
Total Assays
1,394
Tested Compounds
1
Assay Types
Binding — 391 assays, 1,394 compounds
BAO Format Assays Compounds Avg pChEMBL
single protein format 290 824 6.8
cell-based format 52 496 7.5
assay format 49 74 6.8

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine